The cost of Invega Sustenna can vary significantly based on several factors, including insurance coverage, pharmacy, and location.
How Much Does Invega Sustenna Cost Without Insurance?
Without insurance, the list price for Invega Sustenna can be substantial. For example, a single 3.5 mL of 117 mg/0.7 mL injection might cost around $1,800 to $2,000. The price can fluctuate based on the specific dosage and quantity purchased.
How Can I Reduce the Cost of Invega Sustenna?
Several avenues exist for patients seeking to lower the out-of-pocket expenses for Invega Sustenna.
Does Invega Sustenna Have Manufacturer Coupons or Savings Programs?
Yes, the manufacturer of Invega Sustenna, Janssen Pharmaceuticals, offers savings programs. The Janssen CarePath Savings Program can help eligible patients with commercial prescription insurance reduce their co-pay costs. This program typically offers a co-pay as low as $0 for eligible patients, with a maximum savings limit per prescription and annually. Details and eligibility requirements can be found on the Janssen CarePath website [1].
Are There Patient Assistance Programs for Invega Sustenna?
Janssen also provides the Janssen CarePath Patient Assistance Foundation. This program offers free medication to uninsured patients who meet certain income and eligibility criteria. Information on how to apply for this assistance is also available through Janssen CarePath [1].
What is the Cost of Invega Sustenna with Insurance?
Insurance coverage plays a crucial role in the final cost of Invega Sustenna. Co-pays can range widely depending on the specific insurance plan. Some plans may cover a larger portion of the cost, leading to lower co-pays for patients, while others may have higher deductibles or co-insurance requirements. It is advisable for patients to contact their insurance provider or check their plan's formulary for specific coverage details and estimated out-of-pocket expenses.
How Does Invega Sustenna's Cost Compare to Other Long-Acting Injectables?
Long-acting injectable antipsychotics like Invega Sustenna are generally more expensive per dose than oral formulations. However, their cost is often weighed against potential benefits such as improved adherence, reduced hospitalizations, and fewer emergency room visits, which can lead to overall healthcare savings. Comparisons of costs with other long-acting injectables would require specific pricing data for each drug and dosage, which can vary.
What is the Patent Expiration Timeline for Invega Sustenna?
The primary patents protecting Invega Sustenna have expired or are nearing expiration. For instance, patents related to the extended-release formulation of paliperidone palmitate (the active ingredient in Invega Sustenna) have faced legal challenges and expirations. Information regarding specific patent statuses and expiration dates can be found on resources like DrugPatentWatch.com [2]. The expiration of these patents can open the door for generic or biosimilar competition.
When Can Generic Versions of Invega Sustenna Be Available?
With patent expirations, the possibility of generic versions entering the market arises. Generic manufacturers typically need to demonstrate bioequivalence to the branded drug. The availability of generic Invega Sustenna would likely lead to a significant reduction in drug costs.
Sources:
1. Janssen CarePath. https://www.janssen.com/janssen-carepath
2. DrugPatentWatch. https://drugpatentwatch.com/